Clinical Trial Protocol
Iranian Registry of Clinical Trials

25 Nov 2026

Effect of Cyanrol in treatment of Non-alcoholic fatty liver disease: a randomized double-blind clinical trial including plaebo

Protocol summary

Summary

This study was designed as a double-blind randomized controlled trial on 100 Non-Alcoholic Fatty Liver patients. At start of study the patient of both groups evaluated for demographic variables, past medical history, age, height, BMI, duration of exercise per day, and diet. Adults (age > 18 y) with a diagnosis of Fatty Liver disease and a negative history of Hypersensitivity to cynarol and Artichoke were recruited to the trial. Subjects with biliary diseases, Statin-treated Hyperlipidemia, pregnancy and lactation were excluded from the trial. Participants were randomized to Cynarol (600 mg/day in three divided doses) and control groups and were treated for a period of 8 weeks. Response to treatment was evaluated using liver Doppler sonography at baseline and at the end of study. Determination of serum levels of hepatic transaminases, total and direct bilirubin, uric acid, lipids and glucose was also performed both at the start and end of the trial.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT2015122125641N1**
Registration date: **2016-08-31, 1395/06/10**
Registration timing: **retrospective**

Last update:
Update count: **0**

Registration date

2016-08-31, 1395/06/10

Registrant information

Name

Parisa Kianpour

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 21 2660 2854

Email address

pk.pioneer1@yahoo.com

Recruitment status

Recruitment complete

Funding source

Vice chancellor for research of Baqiyatallah University of Midecial Science

Expected recruitment start date

2016-02-20, 1394/12/01

Expected recruitment end date

2016-06-18, 1395/03/29

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Effect of Cyanrol in treatment of Non-alcoholic fatty liver disease: a randomized double-blind clinical trial including plaebo

Public title

The efficacy of Cynarol in treatment of non-alcoholic fatty liver disease

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria: patient has Fatty Liver; The history of allergic reaction to the drug combination is not relevant; Over 18 years old; The patient has informed consent to participate in the study; Exclusion criteria: The patient who stops the medication more than 1 week; The patient with the history of biliary disease; The patient with Fatty Liver, who also has Hyperlipidemia and receives statins; Patient with Fatty Liver, who also has another liver

disease; Pregnancy and lactation; The patient who expresses uncontrolled adverse effects by this drug; Alcohol consumption and any addictive drugs..

Age

From **18 years** old to **139 years** old

Gender

Both

Phase

2-3

Groups that have been masked

No information

Sample size

Target sample size: **100**

Randomization (investigator's opinion)

Randomized

Randomization description

Blinding (investigator's opinion)

Double blinded

Blinding description

Placebo

Used

Assignment

Parallel

Other design features

It is a double-blind clinical trail in which neither patients nor analysis technician have no information about the kind of pharmacotherapy(drug or placebo) were received by patients.

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ettics committee of Baqiyatallah University of Medical Science

Street address

Baqiyatallah University of Medical Science, Mollasadra St., Vanak

City

Tehran

Postal code

Approval date

2014-06-08, 1393/03/18

Ethics committee reference number

s/340/221

Health conditions studied

1

Description of health condition studied

Fatty liver

ICD-10 code

k76.0

ICD-10 code description

Fatty (change of) liver, not elsewhere classified

Primary outcomes

1

Description

The accumulation of liver fat

Timepoint

Before the intervention, 8 weeks later at the end of the intervention

Method of measurement

Color Doppler Ultrasonography

Secondary outcomes

1

Description

LDL

Timepoint

Before the intervention, 8 weeks later at the end of the intervention

Method of measurement

Blood test

2

Description

HDL

Timepoint

Before the intervention, 8 weeks later at the end of the intervention

Method of measurement

Blood test

3

Description

Portal vein diameter

Timepoint

Before the intervention, 8 weeks later at the end of the intervention...

Method of measurement

Color Doppler Ultrasonography

4

Description

TG

Timepoint

Before the intervention, 8 weeks later at the end of the intervention

Method of measurement

Blood test

5

Description

Total Cholesterol

Timepoint

Before the intervention, 8 weeks later at the end of the

intervention

Method of measurement

Blood test

6

Description

FBS

Timepoint

Before the intervention, 8 weeks later at the end of the intervention

Method of measurement

Blood test

7

Description

HbA1C

Timepoint

Before the intervention, 8 weeks later at the end of the intervention

Method of measurement

Blood test

8

Description

Uric Acid

Timepoint

Before the intervention, 8weeks later at the end of the intervention

Method of measurement

Blood test

9

Description

Hepatic blood flow velocity

Timepoint

before the intervention8weeks later at the end of intervention

Method of measurement

Color Doppler Ultrasonography

10

Description

ALT

Timepoint

before the intervention,8 weeks later at the end of intervention

Method of measurement

Blood test

11

Description

AST

Timepoint

before the intervention,8 weeks later at the end of intervention

Method of measurement

Blood test

Intervention groups

1

Description

Cynarol,200 mg oral tablet, 3 times a day for 8 weeks

Category

Treatment - Drugs

2

Description

placebo,200mg oral tablet,3 times a day for 8 weeks

Category

Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center

Baqiyatallah hospital

Full name of responsible person

Mohtashami Reza(internist)

Street address

Baqiyatallah hospital, Mollasadra Ave., Vanak

City

Tehran

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Vice chancellor for research of Baqiyatallah University of Medical Science

Full name of responsible person

Ahmadi Morteza(The Deputy Director of Research and Technology of Baqiyatallah University of Medical

Street address

Baqiyatallah University of Medical Science, South Sheikhbahaee St. , Mollasadra Ave., Vanak

City

Tehran

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Vice chancellor for research of Baqiyatallah University of Medical Science

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin
Type of organization providing the funding
empty

Person responsible for general inquiries

Contact
Name of organization / entity
Islamic Azad University of Pharmaceutical Science
Full name of responsible person
Kianpour Parisa
Position
Pharm.D student
Other areas of specialty/work
Street address
Yakhchal St., Shariati Ave.
City
Tehran
Postal code
Phone
+98 21 2264 0051
Fax
Email
pk.pioneer1@yahoo.com; pkp.pioneer1@gmail.com
Web page address

Person responsible for scientific inquiries

Contact
Name of organization / entity
Baqiyatallah University of Medical Science
Full name of responsible person
Panahi Yunes
Position
Clinical Pharmacist
Other areas of specialty/work
Street address
Baqiyatallah University of Medical Science, South Sheikhbahaee St. , Mollasadra Ave., Vana
City
Tehran
Postal code
Phone
+98 21 8821 1524
Fax
Email
yunespanahi@yahoo.com; pk.pioneer1@yahoo.com
Web page address

Person responsible for updating data

Contact
Name of organization / entity
Islamic Azad University of Pharmaceutical Sceince
Full name of responsible person
Kianpour Parisa
Position
Pharm.D student
Other areas of specialty/work
Street address
Yakhchal St., Shariati Ave.
City
Tehran
Postal code
Phone
Fax
Email
pk.pioneer1@yahoo.com; pkp.pioneer1@gmail.com
Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)
empty
Study Protocol
empty
Statistical Analysis Plan
empty
Informed Consent Form
empty
Clinical Study Report
empty
Analytic Code
empty
Data Dictionary
empty